SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Organovo Holdings

Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 9.99% in Organovo Holdings, Inc., totaling 1,700,684 shares.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 1,700,684 shares of Organovo Holdings, Inc. Common Stock.
• This ownership represents 9.99% of the total outstanding shares of Organovo Holdings, Inc.
• The shares are held with shared voting power and shared dispositive power, meaning both Armistice Capital and Steven Boyd can jointly control the voting and sale of these shares.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, is deemed to beneficially own the securities held by the Master Fund.
• The acquisition of these securities was stated to be in the ordinary course of business and not for the purpose of changing or influencing the control of Organovo Holdings, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is neutral.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Organovo Holdings, Inc.'s future performance or strategic direction.

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an investment firm and its principal in a publicly traded company. It indicates a notable investment position by Armistice Capital in Organovo Holdings, a company operating in the biotechnology sector, without providing specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital could be viewed positively by other shareholders, signaling confidence in the company. It also identifies a major shareholder whose future actions (e.g., increasing or decreasing stake) could influence the stock.

Key Dates

Keywords

Organovo Holdings, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology, Healthcare